Diaceutics (DXRX) Competitors GBX 165.96 +0.96 (+0.58%) As of 10/3/2025 11:50 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock DXRX vs. YGEN, ABDX, GENI, VRCI, AGL, PRM, IDHC, GDR, DMTR, and LLAIShould you be buying Diaceutics stock or one of its competitors? The main competitors of Diaceutics include Yourgene Health (YGEN), Abingdon Health (ABDX), GENinCode (GENI), Verici Dx (VRCI), ANGLE (AGL), Proteome Sciences (PRM), Integrated Diagnostics (IDHC), genedrive (GDR), Deepmatter Group (DMTR), and LungLife AI (LLAI). These companies are all part of the "diagnostics & research" industry. Diaceutics vs. Its Competitors Yourgene Health Abingdon Health GENinCode Verici Dx ANGLE Proteome Sciences Integrated Diagnostics genedrive Deepmatter Group LungLife AI Diaceutics (LON:DXRX) and Yourgene Health (LON:YGEN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Do analysts recommend DXRX or YGEN? Diaceutics presently has a consensus target price of GBX 175, indicating a potential upside of 5.45%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts clearly believe Diaceutics is more favorable than Yourgene Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Diaceutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Yourgene Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, DXRX or YGEN? Diaceutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Yourgene Health has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Do insiders and institutionals have more ownership in DXRX or YGEN? 32.2% of Diaceutics shares are owned by institutional investors. Comparatively, 23.3% of Yourgene Health shares are owned by institutional investors. 26.3% of Diaceutics shares are owned by company insiders. Comparatively, 64.4% of Yourgene Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is DXRX or YGEN more profitable? Diaceutics has a net margin of -10.90% compared to Yourgene Health's net margin of -27.55%. Diaceutics' return on equity of -7.15% beat Yourgene Health's return on equity.Company Net Margins Return on Equity Return on Assets Diaceutics-10.90% -7.15% -6.06% Yourgene Health -27.55%-27.06%-6.71% Does the media favor DXRX or YGEN? In the previous week, Diaceutics had 5 more articles in the media than Yourgene Health. MarketBeat recorded 5 mentions for Diaceutics and 0 mentions for Yourgene Health. Diaceutics' average media sentiment score of 0.98 beat Yourgene Health's score of 0.00 indicating that Diaceutics is being referred to more favorably in the media. Company Overall Sentiment Diaceutics Positive Yourgene Health Neutral Which has better earnings and valuation, DXRX or YGEN? Diaceutics has higher revenue and earnings than Yourgene Health. Diaceutics is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDiaceutics£34.40M4.08-£2.84M-£0.02-9,220.00Yourgene Health£29.67M0.00-£8.17M-£0.01N/A SummaryDiaceutics beats Yourgene Health on 11 of the 15 factors compared between the two stocks. Get Diaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DXRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DXRX vs. The Competition Export to ExcelMetricDiaceuticsDiagnostics & Research IndustryMedical SectorLON ExchangeMarket Cap£140.43M£48.92M£6.12B£2.60BDividend YieldN/A3.88%5.66%5.30%P/E Ratio-9,220.001.0286.964,421.35Price / Sales4.08505.43588.1499,678.00Price / Cash3.1211.4226.3027.90Price / Book3.622.8412.538.04Net Income-£2.84M£334.07B£3.30B£5.89B7 Day Performance2.76%0.21%3.53%0.98%1 Month Performance16.06%1.02%6.77%6.24%1 Year Performance25.73%-4.01%70.60%149.27% Diaceutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DXRXDiaceutics1.5849 of 5 starsGBX 165.96+0.6%GBX 175+5.4%+25.7%£140.43M£34.40M-9,220.00151YGENYourgene HealthN/AN/AN/AN/A£16.43M£29.67M-51.50253ABDXAbingdon HealthN/AGBX 6.18-0.3%N/A-34.6%£11.97M£6.82M-846.5884GENIGENinCodeN/AGBX 3.90+8.3%N/A-23.8%£11.19M£2.70M-154.152,300Earnings ReportGap DownVRCIVerici DxN/AGBX 0.69+14.8%N/A-89.2%£10.43M£3.34M-27.5619News CoverageNegative NewsGap DownHigh Trading VolumeAGLANGLE1.9492 of 5 starsGBX 2.75flatGBX 40+1,354.5%-64.5%£8.87M£2.62M-57.05650High Trading VolumePRMProteome SciencesN/AGBX 2.04+4.3%N/A-36.3%£6.02M£4.53M-177.39240Gap UpHigh Trading VolumeIDHCIntegrated DiagnosticsN/AGBX 0.52-2.6%N/A+44.2%£3.02M£5.72B0.296,692GDRgenedriveN/AGBX 0.24+4.9%N/A-87.1%£1.48M£676K-10.9343Gap UpHigh Trading VolumeDMTRDeepmatter GroupN/AN/AN/AN/A£1.33M£1.04M-0.11N/AGap DownLLAILungLife AIN/AGBX 3.50-17.6%N/A-68.9%£1.16M£33.87K-0.2815Gap DownHigh Trading Volume Related Companies and Tools Related Companies Yourgene Health Competitors Abingdon Health Competitors GENinCode Competitors Verici Dx Competitors ANGLE Competitors Proteome Sciences Competitors Integrated Diagnostics Competitors genedrive Competitors Deepmatter Group Competitors LungLife AI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:DXRX) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersThis soon could be the most precious company in AmericaCurrently, a brand-new, all-American factory outside San Antonio is becoming the most significant site in the ...True Market Insiders | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredChina’s New Gold Play Could Make your Income SoarChina's New Gold Move Could Pay You up to $1,152/month. China just announced plans to store other nations' ...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Diaceutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Diaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
